Abstract
Summary
ATP is a competitive inhibitor of erythrocyte glucose-6-phosphate dehydrogenase. Inhibition of the normal enzyme and the enzyme of six variants, four of them associated with nonspherocytic congenital hemolytic anemia was investigated. None of the variants manifested undue sensitivity to ATP inhibition. It is concluded that inhibition by physiologic levels of ATP is probably not a major factor in the pathogenesis of hemolysis in these variants.
Get full access to this article
View all access options for this article.